Table 1.
Patient characteristics.
| Characteristics | 89Zr-lumretuzumab a | 89Zr-MMOT0530A | 89Zr-bevacizumab | 89Zr-trastuzumab b |
|---|---|---|---|---|
| Age, median years (range) | 59 (48-72) | 62 (44-70) | 64 (51-68) | 47 (22-73) |
| Number of patients | 9 | 9 | 9 | 9 |
| Male | 5 (56) | 2 (22) | 5 (56) | 2 (22) |
| Female | 4 (44) | 7 (78) | 4 (44) | 7 (78) |
| Tumor type, n (%) | ||||
| Colorectal | 5 (56) | - | - | 1 (11) |
| Breast | 1 (11) | - | - | 8 (89) |
| Oropharyngeal | 1 (11) | - | - | - |
| CUP | 1 (11) | - | - | - |
| Vulvar | 1 (11) | - | - | - |
| Ovarian | - | 2 (22) | - | - |
| Pancreatic | - | 7 (78) | - | - |
| Renal cell | - | - | 9 (100) | - |
| Sites of tumor lesions, n c | ||||
| Adrenal gland | 3 | 3 | 3 | - |
| Bone | 1 | - | 40 | 121 |
| Brain | - | - | 2 | 9 |
| Breast | - | - | - | 2 |
| Intestine | 2 | - | 2 | 1 |
| Kidney | - | - | 16 | - |
| Lung | 34 | 3 | 6 | 2 |
| Liver | - | 7 | 7 | 48 |
| Lymph nodes | 10 | 6 | 9 | 27 |
| Pancreas | - | 4 | 4 | - |
| Pleura | 2 | - | 3 | - |
| Soft tissue d | 10 | 6 | 29 | 6 |
| Spleen | - | - | 1 | 1 |
| Thyroid gland | - | - | 2 | - |
| Uterus | - | 2 | - | - |
| Tumor load, mL (±SD) | 41 (± 25) | 42 (± 22) | 116 (± 67) | 99 (± 133) |
CUP, Cancer of Unknown Primary. a, 89Zr-lumretuzumab PET was performed in patients with HER3-positive disease according to study protocol (Meulendijks et al., CCR 2017). b, 89Zr-trastuzumab PET was performed in patients with HER2-postive disease as part of an extended clinical work-up. c, Sites of tumor lesions comprise sites of primary tumors and sites of metastases at the time of PET imaging. d, Soft tissue lesions include subcutaneous lesions not further specified, intramuscular lesions and abdominal soft tissue lesions.